The Journal of Headache and Pain

Official Journal of the "European Headache Federation" and of "Lifting The Burden - The Global Campaign against Headache"

The Journal of Headache and Pain Cover Image

Volume 15 Supplement 1

Abstracts from the 4th European Headache and Migraine Trust International Congress: EHMTIC 2014

Open Access

EHMTI-0227. Therapeutic effectiveness of sphenopalatine ganglion (SPG) stimulation for cluster headache – pathway registry study interim results at 6 months

  • TP Jürgens1,
  • R Jensen2,
  • H Kaube3,
  • A Böger4,
  • C Gaul5,
  • A Goodman6,
  • A Caparso6 and
  • A May1
The Journal of Headache and Pain201415(Suppl 1):C26

Published: 18 September 2014


Cluster HeadacheAcute PainAttack FrequencyTherapeutic EffectivenessCluster Headache Patient


The Pathway Registry is an open label registry of SPG stimulation therapy for cluster headache treatment. In a previous randomized, double-blind, multi-center study (Pathway CH-1 study) 68% of patients experienced clinically significant improvements.


The aim of this interim analysis is to evaluate acute and/or preventive therapeutic effectiveness at 6 months following insertion of an SPG neurostimulator.


Therapeutic effectiveness (acute pain response following SPG stimulation and/or attack frequency reduction) was analyzed during the first six months following SPG neurostimulator insertion. Acute pain responders achieved relief from moderate or greater pain, or freedom from mild pain in ≥50% of analyzable attacks (with completed diary questions). Frequency responders achieved ≥50% attack frequency reduction at the six month study visit (evaluated over the previous four weeks), versus the 4 week baseline period.


49 patients have been enrolled, 18 completed follow-up through six months[RJ1] (189 days post-insertion, range 149-238). Average baseline attack frequency was 28.4 attacks/week (range 0-70), and the average attack frequency at 6 months was 17.3 attacks/week (range 0-70), a 40% reduction. 67% (12/18) were responders. Of the 12 responders, 67% (N=8) were acute responders, treating 86% of their attacks effectively (N=546). 75% (N=9) were frequency responders; frequency reduced by 90% (from 22.3 at baseline to 2.1 (range 0-8) attacks/week). 5 patients were both acute and frequency responders.


Interim data from a registry of cluster headache patients continues to demonstrate the effectiveness of SPG stimulation therapy.

Authors’ Affiliations

Headache Clinic Dept. of Systems Neuroscience, Medical Center Hamburg-Eppendorf, Hamburg, Germany
Danish Headache Center, Glostrup Hospital University of Copenhagen, Copenhagen, Denmark
Neurologie und Kopfschmerzzentrum Muenchner Freiheit, Neurologie und Kopfschmerzzentrum Muenchner Freiheit, Munich, Germany
Schmerzzentrum, Rotes Kreuz Krankenhaus, Kassel, Germany
Migräne und Kopfschmerzklinik, Migräne und Kopfschmerzklinik, Königstein, Germany
Autonomic Technologies Inc., Autonomic Technologies Inc., Redwood City, USA


© Jürgens et al; licensee Springer. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.